W Wang1,2, X Wen2, W Duan2, X Wang2, Y Chen2, J Dong2, Z Yang2, J Fang2, Z Zhou2, G Yao2, Y Fang2, Y Huang3. 1. Department of Pharmacy, College of Life Sciences, China Jiliang University, Hangzhou, Zhejiang, China. 2. Zhejiang Doer Biologics Corporation, No. 452 Avenue 6, Hangzhou Economic and Technological Development Zone, Hangzhou, 310018, Zhejiang, China. 3. Zhejiang Doer Biologics Corporation, No. 452 Avenue 6, Hangzhou Economic and Technological Development Zone, Hangzhou, 310018, Zhejiang, China. yanshanhuang@doerbio.com.
Abstract
PURPOSE: Both glucagon-like peptide-1 (GLP-1) and glucagon (GCG) belong to the incretin family. This study aimed to investigate the pharmacokinetics and pharmacodynamics of DR10601, a fully recombinant hybrid peptide with dual GLP-1/GCG receptor agonistic activity. METHODS: The agonistic ability of DR10601 was indirectly assessed by inducing cAMP accumulation in Chinese hamster ovary cells transfected with GLP-1R or GCGR in vitro. Following s.c. administration, the plasma pharmacokinetics of DR10601 were analysed in male Sprague-Dawley rats. The antiobesity effects and improved glycaemic control of DR10601 in vivo were evaluated by administering DR10601 to high-fat DIO mice and ICR mice as a single dose or repeated s.c. doses once every 4 days for 24 days. RESULTS: DR10601 exhibits dual agonistic activity on GLP-1 and glucagon receptors. The plasma half-life of DR10601 in Sprague-Dawley rats following s.c. administration was 51.9 ± 12.2 h. In an IPGTT, a single s.c. dose of DR10601 (30 nmol/kg) produced similar glycaemic control effects and a longer duration of action compared to dulaglutide (10 nmol/kg). Compared with that achieved with liraglutide (40 nmol/kg) s.c. administered daily, DR10601 administered s.c. once every 4 days at 90 nmol/kg exerted a nearly equivalent effect on food intake and significantly reduced the body weights of high-fat DIO mice at 24 days. CONCLUSIONS: Repeated administration of DR1060 provides potent and sustained glycemic control and body weight loss effect in high-fat DIO mice. DR10601 is a promising long-acting agent deserving further investigation for the treatment of type 2 diabetes and obesity.
PURPOSE: Both glucagon-like peptide-1 (GLP-1) and glucagon (GCG) belong to the incretin family. This study aimed to investigate the pharmacokinetics and pharmacodynamics of DR10601, a fully recombinant hybrid peptide with dual GLP-1/GCG receptor agonistic activity. METHODS: The agonistic ability of DR10601 was indirectly assessed by inducing cAMP accumulation in Chinese hamster ovary cells transfected with GLP-1R or GCGR in vitro. Following s.c. administration, the plasma pharmacokinetics of DR10601 were analysed in male Sprague-Dawley rats. The antiobesity effects and improved glycaemic control of DR10601 in vivo were evaluated by administering DR10601 to high-fat DIO mice and ICR mice as a single dose or repeated s.c. doses once every 4 days for 24 days. RESULTS: DR10601 exhibits dual agonistic activity on GLP-1 and glucagon receptors. The plasma half-life of DR10601 in Sprague-Dawley rats following s.c. administration was 51.9 ± 12.2 h. In an IPGTT, a single s.c. dose of DR10601 (30 nmol/kg) produced similar glycaemic control effects and a longer duration of action compared to dulaglutide (10 nmol/kg). Compared with that achieved with liraglutide (40 nmol/kg) s.c. administered daily, DR10601 administered s.c. once every 4 days at 90 nmol/kg exerted a nearly equivalent effect on food intake and significantly reduced the body weights of high-fat DIO mice at 24 days. CONCLUSIONS: Repeated administration of DR1060 provides potent and sustained glycemic control and body weight loss effect in high-fat DIO mice. DR10601 is a promising long-acting agent deserving further investigation for the treatment of type 2 diabetes and obesity.
Entities:
Keywords:
Body weight; Glucagon-like peptide-1; Obesity; Type 2 diabetes
Authors: Michaela Prothiwa; Ismail Syed; Mark O Huising; Talitha van der Meulen; Cynthia J Donaldson; Sunia A Trauger; Barbara B Kahn; Alan Saghatelian Journal: J Am Chem Soc Date: 2014-12-12 Impact factor: 15.419
Authors: J A Pospisilik; S A Hinke; R A Pederson; T Hoffmann; F Rosche; D Schlenzig; K Glund; U Heiser; C H McIntosh; H Demuth Journal: Regul Pept Date: 2001-01-12
Authors: Jonathan W Day; Nickki Ottaway; James T Patterson; Vasily Gelfanov; David Smiley; Jas Gidda; Hannes Findeisen; Dennis Bruemmer; Daniel J Drucker; Nilika Chaudhary; Jenna Holland; Jazzminn Hembree; William Abplanalp; Erin Grant; Jennifer Ruehl; Hilary Wilson; Henriette Kirchner; Sarah Haas Lockie; Susanna Hofmann; Stephen C Woods; Ruben Nogueiras; Paul T Pfluger; Diego Perez-Tilve; Richard DiMarchi; Matthias H Tschöp Journal: Nat Chem Biol Date: 2009-07-13 Impact factor: 15.040
Authors: V Salem; C Izzi-Engbeaya; C Coello; D B Thomas; E S Chambers; A N Comninos; A Buckley; Z Win; A Al-Nahhas; E A Rabiner; R N Gunn; H Budge; M E Symonds; S R Bloom; T M Tan; W S Dhillo Journal: Diabetes Obes Metab Date: 2015-11-20 Impact factor: 6.577
Authors: P Marzullo; T Daffara; C Mele; M Zavattaro; A Ferrero; M Caputo; F Prodam; G Aimaretti Journal: J Endocrinol Invest Date: 2022-04-16 Impact factor: 5.467